肾活检红细胞管型与IgA肾病进展
本研究基于PKU-IgAN队列1425例和TESTING试验279例患者,探讨肾活检红细胞管型(RBCC)与IgA肾病肾脏结局的关联。结果显示RBCC阳性患者新月体病变更多、节段性硬化更少,且RBCC与复合肾脏终点风险降低独立相关,尤其在接受免疫抑制治疗的患者中。
要点
- IgA肾病患者中RBCC阳性率在PKU-IgAN队列为37%,TESTING试验为28%。
- RBCC阳性与更多新月体病变和更少节段性硬化相关。
- RBCC与复合肾脏终点风险降低独立相关,尤其在接受免疫抑制治疗患者中。
核心结论
- 肾活检RBCC在IgA肾病中常见,与急性活动性病变发生率较高及更好的肾脏预后相关,尤其在接受免疫抑制治疗的患者中。
研究设计与样本
- 研究纳入PKU-IgAN队列1425例和TESTING试验279例患者,分析RBCC与肾脏结局的关联,采用Cox回归分析。
- RBCC定义为光镜下肾小管内至少见一个管型。
- 肾脏终点为估算肾小球滤过率持续下降30%或终末期肾病或肾脏疾病死亡的复合终点。
主要发现
- PKU-IgAN队列中529例(37%)RBCC阳性,TESTING试验中78例(28%)RBCC阳性。
- RBCC阳性患者较阴性患者新月体病变更多、节段性硬化更少。
临床怎么用
- 肾活检发现RBCC应提示临床关注IgA肾病患者急性活动性病变及免疫抑制治疗下的预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Renal red blood cell casts (RBCC) are common in IgA nephropathy (IgAN), but their role in kidney disease progression of patients with IgAN remains unclear. METHODS: In total, 1425 patients in a Peking University First Hospital IgAN (PKU-IgAN) cohort and 279 patients in the TESTING trial were enrolled to test the association between RBCC and kidney outcome. RBCC was defined as positive (+) when at least one cast was identified within the renal tubules by light microscopy. Kidney endpoint was the composite of the first occurrence of a sustained 30% decrease in estimated glomerular filtration rate or end stage kidney disease or death due to kidney disease. Cox regression analysis was used. RESULTS: In PKU-IgAN, 529 patients (37%) had RBCC; in the TESTING trial, 78 patients (28%) had RBCC. Patients with RBCC had more crescentic lesions, and less segmental sclerosis compared with patients without RBCC. In PKU-IgAN, after a median follow-up of 54 months, 119 patients (22%) with RBCC and 260 patients (29%) without RBCC reached the composite kidney endpoint (P = .009). In multivariable analysis, RBCC was independently associated with composite kidney endpoint [hazard ratios (HR) 0.79; 95% confidence interval (CI) 0.63-0.99; P = .038]. RBCC and immunosuppressive therapy (IST) had an interaction (P = .001). RBCC was independently associated with composite kidney endpoint in patients who received IST (HR 0.56; 95%CI 0.40-0.77; P < .001). In the TESTING trial, after a median follow-up of 57 months, 26 patients (33%) with RBCC, and 96 patients (48%) without RBCC reached the composite kidney endpoint (P = .041). In univariate analysis, RBCC was associated with composite kidney endpoint (HR 0.64; 95%CI 0.42-0.99; P = .047). CONCLUSION: Renal RBCC was frequent in IgAN and was associated with a higher incidence of acute active lesions and better renal prognosis, especially in those who received IST, warranting particular attention.
引用
- Yao YX, Tang C, Shi SF, et al. Red blood cell casts on kidney biopsy and progression of IgA nephropathy. Nephrol Dial Transplant. 2025. PMID: 39909472. doi:10.1093/ndt/gfaf023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。